Adding Dexmedetomidine or Tramadol to Paracetamol- An Effort to Attenuate Catheter Related Bladder Discomfort

Condition(s) studied

Investigational drug(s) / intervention(s)

Dexmedetomidine 0.5 mic/kg: Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg,

Tramadol 1mg/kg: Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.

Paracetamol 10mg/kg: Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.

Study summary

The insertion of a urinary catheter in a patient undergoing a surgical procedure, especially urinary interventions, may lead to catheter-related bladder discomfort (CRBD) with varying degrees of severity during the postoperative period. Paracetamol is a drug with proven efficacy for the management of mild and moderate postoperative pain. Tramadol is a centrally acting, synthetic opioid analgesic with weak opioid agonist properties. It inhibits the detrusor activity by inhibition of type-1 muscarinic (M1) and type-3 muscarinic (M3) receptors. Dexmedetomidine, a highly selective α2-adrenergic receptor agonist, with analgesic, sedative, anxiolysis, sympatholytic, and sedative properties, is a very useful associated agent for general anesthesia.

Eligibility

Primary outcome measure(s)

• The incidence of catheter-related bladder discomfort (CRBD) — 24 hours postoperative
  The incidence of catheter-related bladder discomfort (CRBD) will be assessed at 30 minutes and 1, 2, 4, 6,8,10,12 and 24 hours postoperatively.

Trial sites (1)

More Al-Azhar University trials in Egypt